Cancer screening

Provation and the Australian Commission on Safety and Quality in Health Care strive to improve colonoscopy documentation with new requirements and technology

Retrieved on: 
Tuesday, July 13, 2021
Health, Medicine, Clinical medicine, Cancer screening, Colonoscopy, Diagnostic gastroenterology, Endoscopy, Large intestine, Health care quality, Patient safety organization

In January 2019, funded by the Australian Government Department of Health, the Commission developed the Colonoscopy Clinical Care Standard.

Key Points: 
  • In January 2019, funded by the Australian Government Department of Health, the Commission developed the Colonoscopy Clinical Care Standard.
  • The Standard includes nine quality statements and a set of four clinical indicators for proper colonoscopy procedure care.
  • By reporting on the Commissions indicators, Australian facilities can increase documentation standardisation for colonoscopies and improve quality patient care.
  • The Australian Commission on Safety and Quality in Health Care is an Australian Government agency that leads and coordinates national improvements in the safety and quality of health care based on the best available evidence.

Thynk Health Welcomes Kim Parham as Vice President of Strategic Partnerships and Clinical Liaison

Retrieved on: 
Monday, July 12, 2021
Medicine, Lung cancer, Cancer screening, Health effects of tobacco, Medical terminology, Health, Lung cancer screening, Cancer, Screening

LEXINGTON, Ky., July 12, 2021 /PRNewswire/ -- Thynk Health, the Complete Lung Cancer Screening Solution, announced and welcomed Kim Parham as VP of Strategic Partnerships and Clinical Liaison as the company enters into a new wave of growth and business development.

Key Points: 
  • LEXINGTON, Ky., July 12, 2021 /PRNewswire/ -- Thynk Health, the Complete Lung Cancer Screening Solution, announced and welcomed Kim Parham as VP of Strategic Partnerships and Clinical Liaison as the company enters into a new wave of growth and business development.
  • She is excited to be joining the Thynk Health team offering technology solutions that improve patient outcomes while helping increase facility revenue.
  • Thynk Health is on a mission to save lives lost to lung cancer by disrupting outdated, burdensome lung cancer screening processes.
  • Thynk Health's platform optimizes data-driven workflows and provides operational and clinical analytics for cancer screening programs and incidental findings management.

Exact Sciences schedules second quarter 2021 earnings call

Retrieved on: 
Thursday, July 8, 2021
Branches of biology, Medicine, Medical specialties, Medical genetics, Medical terminology, Exact Sciences, Medical tests, Cancer screening, Medical diagnosis, Screening

A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter answers to give people the clarity to take life-changing action, earlier.

Key Points: 
  • A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter answers to give people the clarity to take life-changing action, earlier.
  • Building on the success of Cologuard and Oncotype tests, Exact Sciences is investing in its product pipeline to support patients throughout their cancer diagnosis and treatment.
  • Exact Sciences unites visionary collaborators to help advance the fight against cancer.
  • For more information, please visit the company's website at www.exactsciences.com , follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on Facebook.

NanoString to Release Second Quarter 2021 Operating Results and Host Conference Call on Wednesday, August 4, 2021

Retrieved on: 
Thursday, July 8, 2021
Science, Health, Research, Medical devices, Cancer screening, NanoString Technologies, Conference call

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that the Company will release second quarter 2021 operating results after the close of the market on Wednesday, August 4, 2021.

Key Points: 
  • NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that the Company will release second quarter 2021 operating results after the close of the market on Wednesday, August 4, 2021.
  • Company management will host a conference call beginning at 4:30pm ET to discuss those results and provide a business update.
  • After registering, an email confirmation will be sent, including dial-in details and unique conference call codes for entry.
  • A replay of the call will be available beginning August 4, 2021 at 7:30pm ET through midnight on August 11, 2021.

The Lung Ambition Alliance: Nearly One Quarter of Deaths From Lung Cancer Could Be Avoided in High-Risk Populations Through Targeted Lung Cancer Screening Worldwide

Retrieved on: 
Thursday, July 8, 2021
Managed care, Research, Radiology, Pharmaceutical, Oncology, Hospitals, Surgery, Science, Cardiology, Biotechnology, Nursing, Medical Supplies, Health, Lung cancer, Cancer, Branches of biology, Clinical medicine, Cancer screening, Cancer staging, TNM staging system, Breast cancer

12 ,13,14 However, screening for lung cancer is not as widely available as for breast and colorectal cancers.15

Key Points: 
  • 12 ,13,14 However, screening for lung cancer is not as widely available as for breast and colorectal cancers.15
    Unfortunately for lung cancer screening, policy change has lagged behind the changing attitudes as new evidence has become available.
  • Mohit Manrao, Vice President and Global Franchise Head of Lung Cancer, AstraZeneca, said: We cannot squander the opportunity to alleviate the burden of lung cancer on society through effective screening.
  • The Lung Ambition Alliance is a flagship partnership of diverse organizations united in the quest to eliminate lung cancer as a cause of death.
  • The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer.

NCCN Maintains Qualification as CMS-Approved Provider-Led Entity for the Development of Imaging Appropriate Use Criteria

Retrieved on: 
Wednesday, July 7, 2021
Medicine, Medical physics, Radiology, Medical imaging, Clinical medicine, Health care, Image processing, Nuclear medicine, Magnetic resonance imaging, Single-photon emission computed tomography, Cancer screening, Tomography

NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC) are accessible for free to registered users of NCCN.org through an easy-to-use database at NCCN.org/ImagingAUC .

Key Points: 
  • NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC) are accessible for free to registered users of NCCN.org through an easy-to-use database at NCCN.org/ImagingAUC .
  • "NCCN is honored to remain among the distinguished group of CMS-approved provider-led entities for development of diagnostic imaging AUC," said Robert W. Carlson, MD, Chief Executive Officer, NCCN.
  • NCCN Imaging AUC are based directly on the NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines ) and include recommendations pertaining to cancer screening, diagnosis, staging, treatment response assessment, follow-up, and surveillance.
  • All imaging procedures recommended in the NCCN Guidelines, including radiographs, computed tomography (CT) scans, magnetic resonance imaging (MRI), functional nuclear medicine imaging (PET, SPECT) and ultrasound, are included within NCCN Imaging AUC.

RamSoft Acquires a Majority Stake in Meddiff to Advance Patient Care Globally

Retrieved on: 
Tuesday, July 6, 2021
Medical imaging, Medicine, Medical physics, Breast imaging, Cancer screening, Mammography, Projectional radiography, Workflow, Radiology, Clinical medicine, Medical tests

RamSoft will continue to be headquartered in Toronto, Canada and the company's management team will be led by President and CEO Vijay Ramanathan.

Key Points: 
  • RamSoft will continue to be headquartered in Toronto, Canada and the company's management team will be led by President and CEO Vijay Ramanathan.
  • "Our commitment to saving patient lives through universal access to imaging is what drives us as a company.
  • To expand its global footprint and support this mission, RamSoftlooked towards Meddiff, a Bangalore-based company that has over 1,500 installed sites globally.
  • Built using cutting-edge, single database technology, our radiology, mammography, and enterprise imaging software enables practices tooptimize their workflow, cut costs, and overall, improve patient care.

RamSoft Acquires a Majority Stake in Meddiff to Advance Patient Care Globally

Retrieved on: 
Tuesday, July 6, 2021
Medical imaging, Medicine, Medical physics, Breast imaging, Cancer screening, Mammography, Projectional radiography, Workflow, Radiology, Clinical medicine, Medical tests

RamSoft will continue to be headquartered in Toronto, Canada and the company's management team will be led by President and CEO Vijay Ramanathan.

Key Points: 
  • RamSoft will continue to be headquartered in Toronto, Canada and the company's management team will be led by President and CEO Vijay Ramanathan.
  • "Our commitment to saving patient lives through universal access to imaging is what drives us as a company.
  • To expand its global footprint and support this mission, RamSoftlooked towards Meddiff, a Bangalore-based company that has over 1,500 installed sites globally.
  • Built using cutting-edge, single database technology, our radiology, mammography, and enterprise imaging software enables practices tooptimize their workflow, cut costs, and overall, improve patient care.

Olympus Supports New Recommendation to Begin Colorectal Cancer Screenings at Age 45

Retrieved on: 
Thursday, July 1, 2021
Medicine, Clinical medicine, Health, Diagnostic gastroenterology, Colorectal cancer, Cancer screening, Medical terminology, Prevention, Colonoscopy, United States Preventive Services Task Force, Cancer, Screening

CENTER VALLEY, Pa., July 1, 2021 /PRNewswire/ -- Today, Olympus announced its support of the new recommendation issued by the United States Preventive Services Task Force (USPSTF) to begin colorectal cancer screenings for all individuals beginning at age 45.

Key Points: 
  • CENTER VALLEY, Pa., July 1, 2021 /PRNewswire/ -- Today, Olympus announced its support of the new recommendation issued by the United States Preventive Services Task Force (USPSTF) to begin colorectal cancer screenings for all individuals beginning at age 45.
  • Age is one of the most prominent risk factors of colorectal cancer, with 94% of cases found in those who are 45 years or older.
  • "This cause is meaningful to Olympus as the pioneering manufacturer of endoscopic devices used to detect and treat colorectal cancer, and it's very meaningful to me personally as I lost my father to colorectal cancer.
  • Research shows that this new age recommendation is important for all, but crucial for Black individuals because early onset colorectal cancer is much more common.6
    To learn more about colorectal cancer and screenings, visit Colonoscopy Today .

QIAGEN Forms Strategic Alliance With Sysmex Corporation for Global Cancer Companion Diagnostics Development and Commercialization Using NGS and Plasma-Safe-SeqS Technology

Retrieved on: 
Thursday, July 1, 2021
Oncology, Health, Other Science, Pharmaceutical, Science, Biotechnology, Medicine, Clinical medicine, Medical software, Qiagen, Cancer screening, Liquid biopsy, Biopsy, QIAGEN, Sysmex, QIAGEN, SYSMEX

The alliance aims to foster collaborations with pharmaceutical companies for the development of drug treatments for cancer and promote early clinical adoption of ultra-sensitive liquid biopsy companion diagnostics.

Key Points: 
  • The alliance aims to foster collaborations with pharmaceutical companies for the development of drug treatments for cancer and promote early clinical adoption of ultra-sensitive liquid biopsy companion diagnostics.
  • Cancer companion-diagnostics products will be launched by QIAGEN and Sysmex in various regions of the world.
  • Liquid biopsy addresses these challenges and, in combination with sensitive NGS, allows the evaluation of patients at different points of their cancer treatment.
  • The alliance with QIAGEN promises Sysmex a great application for Sysmexs Plasma-Safe-SeqS technology, which can detect gene mutations of cancer in blood with ultra-high sensitivity.